Research Article
Open Access
Pharmacokinetics of A New Oral Controlled-Release Formulation of Doxycycline Hyclate for Dogs
Sara Melisa Arciniegas Ruizᵃ, Lilia Gutierrez Olveraᵃ, Maria Josefa Bernad Bernadᵇ, Dinorah Vargas Estradaᵃ*
ᵃ Departamento de Fisiología y Farmacología, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México. México. ᵇ Departamento de Farmacia. Facultad de Química, Universidad Nacional Autónoma de México, México
Sara Melisa Arciniegas Ruizᵃ, ᵃ Departamento de Fisiología y Farmacología, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México. México.ᵇ Asian Journal of Pharmacology and Toxicology 02 (05); 2014; 01-06.
Abstract
The aim of this study was to develop an oral drug formulation of doxycycline hyclate that maintain longer therapeutic levels than conventional forms. A polymethacrylate and acrylic acid based matrix were used in different proportions to obtain controlled-release formulations; DOX1, DOX2 and DOX-C (without excipients). Serum concentrations vs. time profile were investigated after their oral administration in healthy dogs. DOX1 and DOX2 showed therapeutic concentrations for 60 hours, while DOX-C only 24 hours. The pharmacokinetic values obtained were K½el, Cmax, Tmax, AUC, AUC∞, AUCt, AUMC, RT, Kel, Vdss, Clb and Frel. DOX1 did not differ significantly from DOX-C but showed significant differences in all variables with DOX2 (p<0.05). In conclusion DOX1 had the best pharmacokinetics-pharmacodynamics relationship for time-dependent drug and longer release time (60 hours), thereby reducing the frequency of administration, the patient's stress, the occurrence of adverse effects and the cost of treatment.
Keywords
canine, carbopol, eudragit, long-acting.
Full text content is not available right now.